Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625001168448
Ethics application status
Approved
Date submitted
7/10/2025
Date registered
27/10/2025
Date last updated
27/10/2025
Date data sharing statement initially provided
27/10/2025
Type of registration
Retrospectively registered
Titles & IDs
Public title
Evaluating the impact of Artificial Intelligence (AI) assistance in cardiovascular disease risk assessment for resource-constrained settings: a randomised controlled study with general practitioners in Indonesia
Query!
Scientific title
Evaluating the impact of Artificial Intelligence (AI) assistance in cardiovascular disease risk assessment for resource-constrained settings: a randomised controlled study with general practitioners in Indonesia
Query!
Additional trial identifiers [1]
315520
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
atherosclerotic cardiovascular disease
339112
0
Query!
Condition category
Condition code
Cardiovascular
335400
335400
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
We perform a three-way within-subject randomised design, where doctors as participants completed clinical vignettes or patient cases. For each patient case, participants asses 10-year atherosclerotic cardiovascular disease (ASCVD) risk and made management decisions using either a conceptual prototype of AI-based clinical decision support (CDS), automated CDS, or no decision support. This online study may take approximately 1 hour.
Participants are presented with nine hypothetical patient cases in an outpatient setting. each case present a brief patient history, physical examination, and simple laboratory results that are commonly available in resource-constrained clinical settings. The trial set up and the CDS interface was designed to emulate access on a mobile device which is a likely real-world implementation of such tools in resource-constrained setting
The study is simulated using Gorilla.sc, a platform for conducting online experiments, which is customised to display patient cases and the CDS interventions. Allocation of cases to the different conditions of CDS quality, and the order of presentation are randomised. All randomisations are set equal (1:1) and performed by the Gorilla software. Participants self-enrolled in the online experiment. The study URL is provided in the invitation and participants are asked to access the study from a laptop or desktop computer with an internet connection at a convenient time and place. Participants are instructed to complete all cases to the best of their clinical judgment in a single, uninterrupted session and no time limits were imposed. Participant ID and time are automatically monitored by the software.
This is a within-subject cross-over trial. While participants could distinguish between the control (no decision support) and intervention conditions, they were blinded to the nature of the intervention. The Automated CDS and AI-based CDS are presented as “Risk Calculator 1” and “Risk Calculator 2” respectively, without disclosure of which system incorporated AI. This approach is designed to minimise placebo effects that could influence clinician performance. No formal washout period was required, as the interventions are software-based and delivered in a blinded, counterbalanced sequence to mitigate carryover effects.
Query!
Intervention code [1]
332141
0
Early detection / Screening
Query!
Description of the comparator or control
The control group is cases with No decision support i.e. the current approach to risk assessment served as the control condition. Each case present a brief patient history, physical examination, and simple laboratory results that are commonly available in resource-constrained clinical settings
Risk factors, risk assessment, and patient management in each case are coded by a GP and reviewed by a cardiologist consultant; disagreements were resolved by consensus. The gold standard for risk assessment was determined prior to the study based on the clinical guidelines. Cases and gold standard responses for correct risk assessment and patient management were independently reviewed by an expert panel of two other senior cardiology consultants to ensure clinical relevance.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
342975
0
Risk assessment
Query!
Assessment method [1]
342975
0
We count the number of cases correctly assessed against the validated gold standard response for the case. The response is collected from the web platform.
Query!
Timepoint [1]
342975
0
Asses at the conclusion of the study
Query!
Primary outcome [2]
342976
0
Aspirin prescription
Query!
Assessment method [2]
342976
0
We count the number of cases correctly managed against the validated gold standard response for the case. The response is collected from the web platform.
Query!
Timepoint [2]
342976
0
Asses at the conclusion of the study
Query!
Primary outcome [3]
342977
0
Statin prescription
Query!
Assessment method [3]
342977
0
We count number of cases correctly manage
Query!
Timepoint [3]
342977
0
Asses at the conclusion of the study
Query!
Secondary outcome [1]
452983
0
Technology Acceptance
Query!
Assessment method [1]
452983
0
Technology acceptance method 7-likert scale
Query!
Timepoint [1]
452983
0
Immediately after assessing all the patient cases
Query!
Secondary outcome [2]
453364
0
Decision-making time
Query!
Assessment method [2]
453364
0
Decision-making time is measured from when the case was first presented until the responses for risk assessment and diagnosis were submitted.
Query!
Timepoint [2]
453364
0
Immediately after assesing the patient case, automatically measured by the platform
Query!
Secondary outcome [3]
453365
0
Anti-hypertensive prescription (Primary Outcome)
Query!
Assessment method [3]
453365
0
We count the number of cases correctly managed against the validated gold standard response for the case. The response is collected from the web platform.
Query!
Timepoint [3]
453365
0
Assess at the conclusion of the study
Query!
Secondary outcome [4]
453366
0
Advanced examination referral (Primary Outcome)
Query!
Assessment method [4]
453366
0
We count the number of cases correctly managed against the validated gold standard response for the case. The response is collected from the web platform.
Query!
Timepoint [4]
453366
0
Asses at the conclusion of the study
Query!
Eligibility
Key inclusion criteria
Indonesian doctors who are working in general practice or enrolled in a cardiology training program are eligible to participate.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
Did not complete consent
Did not finish instructions and all study tasks
Did not complete pre-study and post-study consent
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants are allocated to sequences at the time of enrolment using balanced randomisation, with sequences presented in random order by Gorilla platform.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The allocation of patient cases to CDS type is according to 9 pre-generated sequences, created so that cases are allocated evenly across each of the three conditions.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
effects of CDS are tested using Friedman’s test comparing three-way multiple repeated measures of cases correctly assessed and managed across interventions.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
31/12/2024
Query!
Date of last data collection
Anticipated
Query!
Actual
31/12/2024
Query!
Sample size
Target
61
Query!
Accrual to date
Query!
Final
102
Query!
Recruitment outside Australia
Country [1]
27421
0
Indonesia
Query!
State/province [1]
27421
0
Query!
Funding & Sponsors
Funding source category [1]
320117
0
University
Query!
Name [1]
320117
0
Macquarie University
Query!
Address [1]
320117
0
Query!
Country [1]
320117
0
Australia
Query!
Funding source category [2]
320118
0
Government body
Query!
Name [2]
320118
0
NHMRC
Query!
Address [2]
320118
0
Query!
Country [2]
320118
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Macquarie University
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
322677
0
None
Query!
Name [1]
322677
0
Query!
Address [1]
322677
0
Query!
Country [1]
322677
0
Query!
Other collaborator category [1]
283703
0
University
Query!
Name [1]
283703
0
Universitas Indonesia
Query!
Address [1]
283703
0
Query!
Country [1]
283703
0
Indonesia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
318666
0
Macquarie University Human Research Ethics Committee Medical Sciences
Query!
Ethics committee address [1]
318666
0
https://www.mq.edu.au/research/ethics-integrity-and-policies/ethics/human-ethics
Query!
Ethics committee country [1]
318666
0
Australia
Query!
Date submitted for ethics approval [1]
318666
0
11/11/2021
Query!
Approval date [1]
318666
0
02/05/2022
Query!
Ethics approval number [1]
318666
0
10328
Query!
Ethics committee name [2]
318667
0
Fakultas Kedokteran Universitas Indonesia
Query!
Ethics committee address [2]
318667
0
Jl. Salemba Raya No 6, Jakarta 10430 PO Box 1358
Query!
Ethics committee country [2]
318667
0
Indonesia
Query!
Date submitted for ethics approval [2]
318667
0
14/06/2022
Query!
Approval date [2]
318667
0
20/06/2022
Query!
Ethics approval number [2]
318667
0
22-06-0746
Query!
Summary
Brief summary
This is a randomised controlled study to understand the effect of AI-based CDS on cardiovascular risk assessment and patient preventive management. We recruit general practitioners as participants. Participant will complete clinical vignettes or patient cases. For each cases, participant make decision of risk assessment and management using either AI-based CDS, automated CDS, or no decision support.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
144862
0
Prof Farah Magrabi
Query!
Address
144862
0
Macquarie University, Australian Institute of Health Innovation, LEVEL 6, 75 TALAVERA RD, NSW 2113
Query!
Country
144862
0
Australia
Query!
Phone
144862
0
+61 2 9850 2429
Query!
Fax
144862
0
Query!
Email
144862
0
[email protected]
Query!
Contact person for public queries
Name
144863
0
Anindya Susanto
Query!
Address
144863
0
Macquarie University, Australian Institute of Health Innovation, LEVEL 6, 75 TALAVERA RD, NSW 2113
Query!
Country
144863
0
Australia
Query!
Phone
144863
0
+61423309268
Query!
Fax
144863
0
Query!
Email
144863
0
[email protected]
Query!
Contact person for scientific queries
Name
144864
0
Anindya Susanto
Query!
Address
144864
0
Macquarie University, Australian Institute of Health Innovation, LEVEL 6, 75 TALAVERA RD, NSW 2113
Query!
Country
144864
0
Australia
Query!
Phone
144864
0
+61423309268
Query!
Fax
144864
0
Query!
Email
144864
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
•
Researchers
Conditions for requesting access:
•
Yes, conditions apply:
•
Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
•
Requires approval by an ethics committee
What individual participant data might be shared?
•
De-identified individual participant data:
•
Published results
•
Primary outcome(s)
What types of analyses could be done with individual participant data?
•
Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
A finite period of:
5
years
Where can requests to access individual participant data be made, or data be obtained directly?
•
Email of trial custodian, sponsor or committee:
contact
[email protected]
(corresponding) or
[email protected]
(Principal investigator)
Are there extra considerations when requesting access to individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
AI-Assisted Cardiovascular Risk Assessment by General Practitioners in Resource-Constrained Indonesian Settings Using a Conceptual Prototype: Randomized Controlled Study.
2025
https://dx.doi.org/10.2196/73131
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF